Coverage
Health
- Today so far
- 0signals
- Last 7 days
- 299signals
- Against the 7 days before
- 9% more
- 711/8
- 479
- 5210
- 5011
- 5012
- 4513
- 2314
- 1615
- 5516
- 6017
- 5118
- 5119
- 5120
- 1521
- 0Today
- Retracted UK Study on Pan-Sars-CoV-2 Vaccine Design Raises ConcernsA 2022 study on a vaccine design for broader coronavirus immunity was retracted after its author admitted to data fabrication, raising concerns but not undermining the broader field of vaccine research.NewHealth1 sources · 5 evidence2026-11-22 08:00
- Virginia child dies in state's first measles-associated death of 2026A four-year-old-or-younger child in Virginia died from measles, marking the state's first measles-associated death of 2026 and adding to a national outbreak that caused the US to lose its measles elimination status after 26 years.NewHealth1 sources · 14 evidence2026-11-21 23:30
- Measles outbreak prompts travel advisory in USThe US has lost its measles elimination status due to an outbreak, leading to travel advisories and 13 deaths and 7,700 infections since 2025.NewHealth1 sources · 10 evidence2026-11-21 19:30
- Caliway's CBL-514 Receives Early IND Clearance in ChinaCaliway Biopharmaceuticals' China clinical trial (CBL-0102) for the injectable drug candidate CBL-514 received early authorization to proceed from China's NMPA ahead of schedule, with subject enrollment expected to begin in December 2026 and clinical data anticipated in Q2 2027.StableHealth1 sources · 1 primary · 2 evidence2026-11-20 13:14
- Pennsylvania logs eighth measles death; survey reveals widespread misunderstanding of disease risksPennsylvania reported its eighth measles-related death, raising the U.S. total to 11, while a new Annenberg Public Policy Center survey of over 1,000 adults found that nearly 60% of respondents did not know the measles death rate, and only one in 10 correctly identified it as about 1 in 1,000. The survey also revealed that just one-third of Americans knew children need two MMR vaccine doses for full protection.StableHealth1 sources · 6 evidence2026-11-20 11:00
- Malaria antibody L9LS protects infants but blunts R21 vaccine responseA Phase 1b trial in Mali found a single intramuscular dose of the monoclonal antibody L9LS safely provided 78% protective efficacy against malaria infection in infants aged 1-12 months during the six-month transmission season, but the antibody appeared to interfere with immune response to subsequent R21 vaccination, pausing plans for larger infant trials.StableHealth2 sources · 15 evidence2026-11-20 06:45
- Isomorphic Labs and MSD announce strategic AI-driven drug discovery collaborationIsomorphic Labs and MSD (Merck) announced a strategic collaboration to discover small-molecule therapeutic candidates targeting a strategically important oncology indication. Isomorphic Labs will apply its IsoDDE AI platform for in silico predictions and molecular design, while MSD will lead preclinical and clinical development, manufacturing, and commercialization.StableHealth1 sources · 1 primary · 14 evidence2026-11-20 23:46
- Hagens Berman investigation launched into Madrigal Pharmaceuticals over whistleblower clinical data integrity claimsHagens Berman announced an investigation into Madrigal Pharmaceuticals following a whistleblower complaint filed in October 2026 alleging suppressed liver-injury data, efficacy discrepancies, and improper board oversight of Rezdiffra clinical trials. The firm is examining whether executives misrepresented data integrity and regulatory compliance.StableHealthPolicy1 sources · 1 primary · 2 evidence2026-11-20 01:04
- U.S. loses measles elimination status with rising outbreaksThe United States has officially lost its measles elimination status from the Pan American Health Organization, driven by surging outbreaks and declining vaccination coverage. A preliminary NEJM Evidence analysis finds pregnant women face tenfold higher mortality risks from measles due to immune suppression, and national MMR vaccination coverage among kindergartners dropped to 92.4% in the 2025–2026 school year.StableHealth1 sources · 11 evidence2026-11-20 00:40
- Johnson & Johnson submits sNDA to FDA for CAPLYTA in bipolar maniaJohnson & Johnson filed a supplemental New Drug Application with the U.S. FDA seeking approval of CAPLYTA (lumateperone) for the treatment of manic or mixed episodes associated with bipolar I disorder in adults, based on two positive Phase 3 studies showing rapid symptom improvement.StableHealth1 sources · 1 primary · 2 evidence2026-11-19 21:01
- GLP-1 drugs reduce UK grocery spending by £1bnResearch by Worldpanel by Numerator shows that GLP-1 drugs are causing UK households with users to spend £1bn less on groceries, with a focus on impulse and indulgence products.StableHealth1 sources · 16 evidence2026-11-19 20:18
- CMS proposes CRUSH rule to strengthen healthcare fraud oversightThe Centers for Medicare & Medicaid Services proposed a rule to revise provider enrollment, medical review, and investigation provisions across Medicare, Medicaid, CHIP, and Marketplace programs, aiming to strengthen fraud detection and program integrity oversight.StableHealth1 sources · 1 primary · 21 evidence2026-11-19 13:00
- Implantica Reports Q3 2026 Interim Results with FDA Approval and U.S. LaunchImplantica secured FDA approval for RefluxStop® and launched in the U.S., with significant sales growth in Europe. The company also reported financial results for Q3 2026.StableHealth1 sources · 1 primary · 17 evidence2026-11-19 15:48
- Evotec and Bristol Myers Squibb Receive Second IND Acceptance for Protein Degradation PartnershipEvotec and Bristol Myers Squibb received FDA IND acceptance for a second candidate in their strategic protein degradation partnership, expanding their pipeline of novel molecular glue degraders for high-value targets in oncology.StableHealth1 sources · 1 primary · 2 evidence2026-11-19 15:06
- Sanofi's next-generation rabies vaccine receives EU approvalSanofi announced that its next-generation rabies vaccine VaxRabeo has received approval from the European Union for use in all age groups, featuring a longer shelf life and improved thermal stability.StableHealth1 sources · 9 evidence2026-11-19 14:52
- Novo Nordisk research shows that semaglutide can significantly reduce BMI in obese children.The Phase 3 STEP Young trial by Novo Nordisk found that after 68 weeks of semaglutide treatment, the average BMI of obese children decreased by 13.5%, with 40% of children no longer classified as obese.StableHealth1 sources · 6 evidence2026-11-19 13:19
- AstraZeneca Secures FDA Approval for Imfinzi Combo in MIBCAstraZeneca received FDA approval for Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for treating muscle-invasive bladder cancer (MIBC).StableHealth1 sources · 10 evidence2026-11-19 11:45
- Ionis and Otsuka's ulefnersen meets primary endpoint in FUS-ALS phase 3 trialThe phase 3 FUSION trial met its primary endpoint, showing a statistically significant improvement in a combined measure of function and survival for FUS-ALS patients treated with ulefnersen versus placebo. This is the first placebo-controlled ALS trial targeting a genetic cause to meet its primary endpoint.StableHealth1 sources · 7 evidence2026-11-19 08:00
- Unvaccinated Pennsylvania resident dies amid historic US measles resurgenceAn unvaccinated Pennsylvania resident died in 2026, the eighth measles-related fatality in the state, as the US formally lost its 26-year measles elimination status after PAHO reviewed transmission data. The outbreak has caused 5,412 confirmed cases nationwide and 1,589 in Pennsylvania across 46 counties.StableHealth1 sources · 5 evidence2026-11-19 08:14
- Congo Ebola outbreak six months on, death toll exceeds 5,500The Democratic Republic of the Congo's Ebola outbreak, now six months old, has infected over 11,000 people and caused more than 5,500 deaths, with the rare Bundibugyo variant spreading at double the initial rate and over 80% of new cases emerging outside known contact lists.StableHealth1 sources · 16 evidence2026-11-19 06:03
- FDA Approves Drug for Infantile-Onset Niemann-Pick Type CThe FDA has approved cyclodextrin (Adrabetadex) for treating infantile-onset Niemann-Pick type C disease, a rare neurodegenerative disorder, after a clinical trial showed extended survival for participants.StableHealth1 sources · 5 evidence2026-11-19 06:00
- New Treatment Strategy for Down Syndrome Shows Promise in Phase 2 Clinical TrialA phase 2 clinical trial found that a JAK inhibitor reduced inflammation and improved skin conditions in people with Down syndrome, potentially opening new avenues for brain health and Alzheimer's disease research.StableHealthPolicy2 sources · 24 evidence2026-11-19 01:45
- CMS Proposes New Fraud Reforms for Healthcare ProgramsCMS proposes new rules to enhance fraud detection and reporting in Medicare, Medicaid, CHIP, and ACA Marketplace, aiming to save $90 billion over a decade.StableHealth1 sources · 2 evidence2026-11-19 00:49
- Ten63 Therapeutics Launches BEYOND-Alpha Program with Chugai PharmaceuticalTen63 Therapeutics launched BEYOND-Alpha, an early adopter program for its BEYOND computational drug design platform, with Chugai Pharmaceutical as the first participant.StableHealth1 sources · 1 primary · 2 evidence2026-11-19 01:10